Q2 2026 Aytu Biopharma Inc Earnings Call Transcript
Key Points
- Aytu BioPharma Inc (AYTU) successfully launched EXXUA, the first and only 5HT1a agonist approved by the FDA for the treatment of major depressive disorder (MDD), offering a novel treatment approach.
- EXXUA demonstrated a neutral sexual profile in clinical studies, with no sexual-related adverse event rates exceeding placebo, and showed no clinically meaningful weight gain compared to placebo.
- The commercial launch strategy for EXXUA is comprehensive, focusing on prescriber adoption and long-term brand growth, supported by a highly motivated sales organization.
- The Aytu RxConnect platform ensures broad patient access by guaranteeing predictable coverage for commercially insured patients and capping out-of-pocket costs at $50 per prescription.
- Early feedback from patients on EXXUA has been positive, with reports of good tolerability and satisfaction, and prescriptions have been written in 27 states, indicating broad opportunity.
- Net revenue for the quarter decreased to $15.2 million from $16.2 million in the prior year, reflecting a decline in the ADHD portfolio and pediatric portfolio revenues.
- Gross margin decreased to 63.5% from 66.5% last year, primarily due to decreased net revenue and transition-related expenses associated with the ADHD authorized generic performance.
- The company reported a net loss of $10.6 million for the quarter, compared to net income of $0.8 million in the prior year period, impacted by derivative warrant liability loss.
- The launch of a generic version of Adzenys by Teva has introduced competition, accounting for approximately 5% of prescriptions, which could impact future ADHD portfolio revenues.
- The company is facing challenges with weather-related disruptions affecting script fulfillment and sales force productivity, impacting the early stages of EXXUA's commercial launch.
Good day, everyone, and welcome to the Aytu Biopharma fiscal 2026 second-quarter earnings call. (Operator Instructions)
It is now my pleasure to hand the floor over to your host, Robert Blum. Sir, the floor is yours.
All right. Thank you very much, and good afternoon, everyone. As the operator indicated, during today's call, we will be discussing Aytu Biopharma's fiscal 2026 second-quarter operational and financial results for the period ended December 31, 2025.
Joining us on today's call is Aytu's Chief Executive Officer, Josh Disbrow; and Ryan Selhorn, the company's Chief Financial Officer.
At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session. I'd like to remind everyone that today's call is being recorded. A replay of today's call will be available by using the telephone numbers and conference ID provided in the press release issued earlier today or by utilizing the link on the company's website under Events and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
